Express for the treatment of inflammatory spine disease, AbbVie JAK inhibitor reaches the primary endpoint of two phase 3 clinical trials

On October 7, 2021, AbbVie announced that its oral JAK inhibitor upadacitinib (upadacitinib, the English trade name is Rinvoq) has been carried out in two adult patients with axial spondylitis (axSpA).
Phase clinical trials reached the primary endpoint
.

Two phase 3 clinical trials in adult patients with axial spondylitis (axSpA) reached their primary endpoints

The results of two phase 3 clinical trials showed that at week 14, whether in patients with non-radiological axial spondyloarthritis (nr-axSpA), or in active ankylosing spondylitis (AS ) patients, compared with placebo, Upa erlotinib group of more patients to spinal arthritis international Association (ASAS) 40 response
.

Patients received statistically significant reductions in symptoms, including back pain and inflammation, as well as improvements in physical function and disease activity

Upa imatinib group more patients reached the international spine arthritis Association (ASAS) 40 response

In patients with active ankylosing spondylitis (AS)

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly better than the placebo group (18%)
.

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly better than the placebo group (18%)
.

In addition, upatinib also reached multiple secondary endpoints of the trial.
The specific results are shown in the figure below
.

The safety data is consistent with previous studies, and no new risks have been found
.

Picture source: reference [1]

In patients with active non-radiological axial spondyloarthritis

In patients with active non-radiological axial spondyloarthritis

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly higher than the placebo group (23%)
.

45% of the patients in the upatinib group met the ASAS40 standard, which was significantly higher than the placebo group (23%)
.

In addition, upatinib also reached multiple secondary endpoints of the trial.
The specific results are shown in the figure below
.

Picture source: reference [2]

"Ankylosing spondylitis is a debilitating disease that can cause severe pain, stiffness, restricted mobility and long-lasting structural damage, which can seriously affect the daily life of patients
.

" Dr.

Upatinib was discovered and developed by AbbVie scientists.
It is a selective and reversible JAK inhibitor that is taken orally once a day
.

In August 2019, it was approved by the U.

Upatinib was discovered and developed by AbbVie scientists.

Reference materials:

[1] AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis.

[1] AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis.

[2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.
Retrieved October 7.
2021.
from https:// upadacitinib-rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-phase-3-study-for-non-radiographic-axial-spondyloarthritis-301395109.
html